Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q4 FY24 Earnings Presentation
33 slides from Metropolis Healthcare's earnings presentation, May 21, 2024
Slide 1: Intimation of Investor Presentation cover letter
Ref: MHL/Sec&Legal/2024-25/14 Date: May 21, 2024 To, BSE Limited National Stock Exchange of India Ltd Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/ Madam, Sub: Intimation of Investor Presentation Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Dis
Slide 2: Reaching Out Responsibly - Investor Presentation May 2024
Reaching Out RESPONSIBLY Investor Presentation – May 2024
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q4 & FY24 Performance
Q4 & FY24 Performance...
Slide 5: Q4FY24 Performance Snapshot
Q4FY24 Performance Snapshot Total Revenue Core Business* Revenue Rs. 313 Crores Rs. 308 Crores 10.7% YoY 15.0% YoY Core Business* Patient Vol. Core Business* RPP 2.98 Mn Rs. 1,034 7.3% YoY 7.2% YoY Core Business* Test Vol. Core Business* RPT 6.07 Mn Rs 506 7.8% YoY 6.7% YoY EBITDA Margin Reported EB
Slide 6: FY24 Performance Snapshot
FY24 Performance Snapshot Total Revenue Core Business* Revenue Rs. 1,189 Crores Rs. 1,166 Crores 3.6% YoY 13.3% YoY Core Business* Patient Vol. Core Business* RPP 11.59 Mn Rs. 1,006 8.8% YoY 4.1% YoY Core Business* Test Vol. Core Business* RPT 23.47 Mn Rs 497 8.8% YoY 4.2% YoY EBITDA Margin Reported
Slide 7: Q4FY24 Key Highlights
Q4FY24 Key Highlights Core Business* Revenue grew at 15.0% Core business revenues grew at 15.0% with 7.3% patient volume growth and 7.2% 01 on account of RPP. Test volume growth stood @ 7.8% and 6.7% on account of RPT B2C revenues grew by 19.6% for Q4FY24 Y-o-Y with Patient Volume growth of B2C reve
Slide 8: Core Business Revenue continues to grow Mid-Teen
1a. Core Business Revenue continues to grow Mid-Teen…. Core Business PPP Contracts Covid PCR & Covid Allied Total Revenues (incl. Hi-Tech) One of the large PPP Contract ended on 8th 13.3% February 2023 -53.2% 3.6% 1,166 67 46 1,189 1,148 1,029 15.0% 21 10.7% -19.9% 308 282 313 267 7 7 5 0 0 Q4FY23 Q
Slide 9: Growth driven by Patient Volume and RPP
1b. …predominantly by Patient Volume growth @ 7.3% & RPP growth @ 7.2% Core Business No. of Patient Visits (In Mn.) Core Business Revenue Per Patient (In Rs.) +8.8% +7.2% +4.1% 10.7 11.6 964 1,034 966 1,006 +7.3% 2.8 3.0 Q4FY23 Q4FY24 FY23 FY24 Q4FY23 Q4FY24 FY23 FY24 Core Business No. of Tests (In
Slide 10: B2C revenue grew by 19.6%
2. B2C revenue grew by 19.6% & B2C revenue in Mumbai grew by 20.0% Revenue Mix Across Segments B2C Revenue (Rs. Crs) B2C contributes 54% of the total revenue in Q4FY24 16.4% 12% 11% 619 B2C revenues grew by 19.6% Y-o-Y with 532 19.6% Q4FY23 52% Q4FY24 54% Volume growth of 7.2% & RPP growth of 11.6%
Slide 11: B2B revenue grew by 11.1%
3. B2B revenue grew by 11.1% & B2B Specialized revenue grew by 12.2% Revenue Mix Across Segments B2B Revenue Mix (Rs. Crs) +10.0% 12% 11% B2B contributes 35% of revenues for Q4FY24 460 418 Q4FY23 52% Q4FY24 54% B2B revenues grew by 11% for Q4FY24 Y-o-Y with +11.1% 36% 35% Volume growth of 7.1% & RPP
Slide 12: TruHealth Packages revenue grew 22.2%
4a. TruHealth Packages revenue grew @ 22.2% Population for Diagnostic Industry Total TruHealth Packages Revenue Illness 6% 22.9% Wellness 172 140 22.2% 39 48 94% Q4FY23 Q4FY24 FY23 FY24 ✓ Revenue from TruHealth Packages has grown by 22.2% on Y-o-Y Our focus is to cater to the balance 94% of basis &
Slide 13: Specialized Test revenue grew 16.5%
4b. Specialized Test revenue grew @ 16.5% with 10.5% volume growth Offers more than 3,000 Innovation & test menu Divided over multiple specialized tests and uniquely expansion is the heart of specialty 102 tests added in specialized subspecialty segments crafted profiles to meet diagnostic & each ye
Slide 14: Expanding Network from 307 to 601 towns in FY24
5. Expanding Network…from 307 to 601 towns in FY24 Laboratory Network - MHL Service Network - MHL Hitech Network Total Network Rationalization Labs + 54 labs Period 1,480 centres Lab network ARC Service network Total 199 Total 4,150 179 Third Party PSCs 4035 155 Owned PSCs 3,612 Laboratory Network 2
Slide 15: Creating a Digital Transformation for business to grow
7. Creating a Digital Transformation for business to grow Enhanced Rapid Second generation Productivity Scalability Community Cloud for better Point of Sale Platform Registration and life-cycle management Invoicing Platform 2.0 Sales CRM with Customer Data customizable Platform enabling CPQ to manag
Slide 16: Specialized and Premium Wellness revenue contribution continues to grow
Specialized and Premium Wellness revenue contribution continues to grow Strong Brand Equity across markets & Doctors Trust and Reliance on Metropolis helps us grow our Specialized & Premium Wellness segment faster than the Industry Q4FY23 Q4FY24 Specialized (Rs. Crs) Premium Wellness (Rs. Crs) Core
Slide 17: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Continue to focus on strengthening the Brand in Focus cities through increase in B2C share while improving the share of Seeding and Other cities through a healthy mix of B2B and B2C driven by large Test menu Core Business Revenue Break-up Q4FY23 Q4
Slide 18: Q4 & FY24 Consolidated Profit & Loss Statement
Q4 & FY24 Consolidated Profit & Loss Statement Q4FY24* FY24* Profit & Loss Statement (Rs. Crs.) Q4FY24 Q4FY23 Y-o-Y FY24 FY23 Y-o-Y (6 months) (15 months) Revenue from Operations 312.8 282.5 10.7% 1,189.5 1148.2 3.6% 331.0 1,207.7 Cost of Operations 230.3 210.0 893.7 843.8 243.6 907.0 EBIDTA (before
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet Mar 24* Mar 24* Assets (Rs. Crs.) Mar-24 Mar-23 Equity & Liabilities (Rs. Crs.) Mar-24 Mar-23 (15 Months) (15 Months) Non-current assets 1237.7 1198.8 1239.2 Equity 1091.0 990.8 1099.3 Property, Plant and Equipment 154.7 137.2 155.9 Equity Share capital 10.2 10.2 10.2 ROU
Slide 20: Consolidated Abridged Cash flow statement
Consolidated Abridged Cash flow statement FY24* Cash Flow Statement (Rs. Crs) FY24 FY23 (15 Months) Profit Before Tax 173.8 187.6 174.7 Adjustments for Depreciation and other items 127.5 104.1 129.9 Operating profit before working capital changes 301.2 291.6 304.6 Changes in working capital -1.4 7.0
Slide 21: Steady Focus on Balance Sheet continues
Steady Focus on Balance Sheet continues Debtor Days Working Capital Days 31 30 Key Highlights 14 ✓ Debtor days as on Mar-24 stood at 30 days 7 as compared to 31 days as on Mar-23 ✓ Cash & Cash Equivalents stood healthy at Mar-23 Mar-24 Rs. 117 crs as of Mar-24 Mar-23 Mar-24 ✓ Working capital days st
Slide 22: Strong Leadership Team
Strong Leadership Team Dr. Sushil Kanubhai Shah Ameera Sushil Shah Surendran Chemmenkotil Chairman & Executive Director Managing Director Chief Executive Officer Strong Leadership Team for Next Level of Growth Dr. Nilesh Shah Rakesh Agarwal Alangadan Kannan Dr. Kirti Z Kazi Ishita Medhekar President
Slide 23: Metropolis 3.0: Opportunity
Metropolis 3.o : Opportunity
Slide 24: Key Pillars of Metropolis 3.0 Strategy
Key Pillars of Metropolis 3.0 Strategy 01. Strengthening the core 02. Expanding to adjacencies; Expand market share in core and newer geographies with Forge New Alliances a focus on specialized and wellness testing, while creating Expanding into adjacencies like complimenting a differentiated Brand
Slide 25: Addressable market expected to increase to ~Rs. 21K Cr by FY26
Addressable market is expected to increase to ~Rs. 21K Cr by FY26… Addressable market size FY23 FY26 CAGR ~INR 101K Cr ~INR 134K Cr 10% Radiology: ~INR 43K Cr Radiology: ~INR 58K Cr Radiology: 10% Indian diagnostics market Pathology: ~INR 76K Cr Pathology: 10% Pathology: ~INR 58K Cr ~INR 58K Cr ~INR
Slide 26: Metropolis to grow faster than the Industry
…Metropolis to grow faster than the Industry Strategy to Win Higher reliability of the Metropolis Brand with Specialized Doctor Network Large Network (including current expansion) to Increase the product suite for Premium help grow faster in Focus Cities and strengthen Wellness and create a sticky c
Slide 27: International business
International business Our International Presence B2B Locations Kenya Zambia Ghana Tanzania Uganda via Franchisee Year of Inception Year of Inception Year of Inception Year of Inception Year of Inception 2013 2015 2014 2018 2022 Samples brought at GRL from 17 7 8 3 1 10+ Countries Labs/Diagnostics L
Slide 28: Metropolis - Certified Great Place to Work
Metropolis – Certified Great Place to Work Metropolis is the First Indian Diagnostic Organization for getting Great Place To Work certification. EMPLOYEE BRAND- Our Identity Attributes that Build Our Culture Trust, Openness, Innovation, Compassion & Growth Mindset Communicate Amplify with Talent Com
Slide 29: Recent Awards and Accolades
Recent Awards and Accolades Period Particulars Metropolis Healthcare wins the Gold Award for Diagnostic Chain of the Year and the Bronze Award for Best CSR Practice in April 2024 Healthcare at the FE Healthcare Excellence Awards 2024. Metropolis's CSR Program MedEngage honoured with the prestigious
Slide 30: Metropolis ESG Initiatives & Outcomes - FY24
Metropolis ESG’ Initiatives & Outcomes – FY24 Promoting Diversity, Making a positive Equity, and Inclusion impact on the Achieved a 30% year- Deployed 67 Electric community through CSR (DEI) with the launch of on-year reduction in Bikes for Sample ‘The Full Circle - Career programs like energy emiss
Slide 31: Metropolis ESG Goals
Metropolis ESG’ Goals Key Focus Areas Goals Targets and KPIs Environment Emissions and Energy Demonstrate Environmental Stewardship • Carbon Neutrality by 2043 through Sustainable Practices • 45% reduction in emissions intensity by 2030 Waste Management • Zero waste in offices by 2030 • Reduce plast
Slide 32: CSR at Metropolis
CSR at Metropolis Too Shy to Ask (TSTA) MedEngage Preventive health Care Project DSEU*( Delhi Skills Outreach and Digital Program Programme Entrepreneurial University) • Metropolis Foundation, the CSR • The MedEngage outreach • 1,702 TB patients were supported • 7 labs fully made functional in arm o
Slide 33: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Rakesh Agarwal - CFO Mr. Shogun Jain / Mr. Sagar Shro
Metropolis Healthcare — Q4 FY24 Earnings Presentation on 6ix